The MAN-EN™ (Multivalent Antibody NK cell Engager) bispecific antibody platform generates molecules that bind to the CD16A receptor on innate immune cells and specific receptors on tumor cells, thereby bringing innate immune cells (NK cells or macrophages) into close proximity with tumor cells. When these two cells are brought together, the immune cells become activated, release cytokines, and specifically kill the tumor cells.

Compared to other antibody-based platforms, MAN-EN™ molecules are generated using a nanobody structure to create bispecific antibodies. These molecules leverage the advantages of nanobodies for multivalent series connection, avoiding the issue of light-heavy chain mispairing that is common with conventional antibodies. Additionally, MAN-EN™ molecules efficiently bind to unique epitopes on the CD16A receptor expressed on NK cells and macrophages, thereby avoiding affinity competition with endogenous IgG in circulation. This enables efficient tumor killing.

The platform's generated molecules can be applied to the treatment of various human diseases, including cancer, autoimmune diseases, inflammation, and chronic conditions.